Baseline characteristics of patients with DHL (N = 311)
| . | n (%) . |
|---|---|
| Patient characteristics | |
| Median age at dx (range) | 60 (19-87) |
| Male | 187 (61) |
| Median year of dx | 2010 |
| Race/Ethnicity | |
| White (non-Hispanic) | 225 (72) |
| Black | 9 (3) |
| Asian | 7 (2) |
| Hispanic | 19 (6) |
| Other/unknown | 51 (16) |
| ECOG PS | |
| 0 | 79 (25) |
| 1 | 142 (46) |
| 2 | 65 (21) |
| 3 | 15 (5) |
| 4 | 6 (2) |
| NA | 4 (1) |
| Median BSA, m2 (range) | 2.0 (1.37-2.80) |
| Median BMI (range) | 27.4 (18.1-47.0) |
| Prior indolent NHL | 67 (22) |
| Disease characteristics | |
| Stage | |
| I | 20 (6) |
| II | 36 (12) |
| III | 49 (16) |
| IV | 206 (65) |
| B symptoms | |
| Present | 139 (45) |
| Absent | 103 (33) |
| NA | 69 (22) |
| Extranodal sites* | |
| 0 | 123 (40) |
| 1 | 100 (32) |
| 2 | 57 (18) |
| 3 | 21 (7) |
| 4 or more | 9 (3) |
| NA | 1 (<1) |
| Bone marrow involvement | |
| Positive | 129 (41) |
| Negative | 162 (52) |
| NA | 20 (6) |
| CNS involvement* | |
| Positive | 23 (7) |
| Negative | 185 (59) |
| NA | 102 (33) |
| Pathology/laboratory characteristics | |
| Histology | |
| DLBCL | 154 (50) |
| BCLU | 150 (48) |
| FL | 7 (2) |
| Partner translocation | |
| BCL2 | 270 (87) |
| BCL6 | 16 (5) |
| Both BCL2 and BCL6 | 25 (8) |
| Cell of origin | |
| GCB† | 181 (58) |
| Non-GCB | 27 (9) |
| NA | 102 (33) |
| Median LDH level, U/L (range) | 545 (120-42 000) |
| LDH level relative to ULN | |
| >ULN | 236 (76) |
| >3× ULN | 103 (33) |
| Median WBC, 103/mL (range) | 6.8 (1-355) |
| WBC relative to ULN | |
| Elevated | 68 (22) |
| Normal | 174 (56) |
| NA | 69 (22) |
| Median albumin level, g/dL (range) | 3.5 (2-5.1) |
| CD10 status | |
| Positive† | 255 (82) |
| Negative | 18 (6) |
| NA | 38 (12) |
| CD20 status | |
| Positive | 269 (86) |
| Negative | 10 (3) |
| NA | 32 (10) |
| . | n (%) . |
|---|---|
| Patient characteristics | |
| Median age at dx (range) | 60 (19-87) |
| Male | 187 (61) |
| Median year of dx | 2010 |
| Race/Ethnicity | |
| White (non-Hispanic) | 225 (72) |
| Black | 9 (3) |
| Asian | 7 (2) |
| Hispanic | 19 (6) |
| Other/unknown | 51 (16) |
| ECOG PS | |
| 0 | 79 (25) |
| 1 | 142 (46) |
| 2 | 65 (21) |
| 3 | 15 (5) |
| 4 | 6 (2) |
| NA | 4 (1) |
| Median BSA, m2 (range) | 2.0 (1.37-2.80) |
| Median BMI (range) | 27.4 (18.1-47.0) |
| Prior indolent NHL | 67 (22) |
| Disease characteristics | |
| Stage | |
| I | 20 (6) |
| II | 36 (12) |
| III | 49 (16) |
| IV | 206 (65) |
| B symptoms | |
| Present | 139 (45) |
| Absent | 103 (33) |
| NA | 69 (22) |
| Extranodal sites* | |
| 0 | 123 (40) |
| 1 | 100 (32) |
| 2 | 57 (18) |
| 3 | 21 (7) |
| 4 or more | 9 (3) |
| NA | 1 (<1) |
| Bone marrow involvement | |
| Positive | 129 (41) |
| Negative | 162 (52) |
| NA | 20 (6) |
| CNS involvement* | |
| Positive | 23 (7) |
| Negative | 185 (59) |
| NA | 102 (33) |
| Pathology/laboratory characteristics | |
| Histology | |
| DLBCL | 154 (50) |
| BCLU | 150 (48) |
| FL | 7 (2) |
| Partner translocation | |
| BCL2 | 270 (87) |
| BCL6 | 16 (5) |
| Both BCL2 and BCL6 | 25 (8) |
| Cell of origin | |
| GCB† | 181 (58) |
| Non-GCB | 27 (9) |
| NA | 102 (33) |
| Median LDH level, U/L (range) | 545 (120-42 000) |
| LDH level relative to ULN | |
| >ULN | 236 (76) |
| >3× ULN | 103 (33) |
| Median WBC, 103/mL (range) | 6.8 (1-355) |
| WBC relative to ULN | |
| Elevated | 68 (22) |
| Normal | 174 (56) |
| NA | 69 (22) |
| Median albumin level, g/dL (range) | 3.5 (2-5.1) |
| CD10 status | |
| Positive† | 255 (82) |
| Negative | 18 (6) |
| NA | 38 (12) |
| CD20 status | |
| Positive | 269 (86) |
| Negative | 10 (3) |
| NA | 32 (10) |
Dx, diagnosis; ECOG PS, Eastern Cooperative Group performance status; BSA, body surface area; BMI, body mass index; NHL, non-Hodgkin lymphoma; CNS, central nervous system; DLBCL, diffuse large B-cell lymphoma; BCLU, B-cell lymphoma unclassifiable with features intermediate between DLBCL and Burkitt lymphoma; FL, follicular lymphoma; GCB, germinal center B-cell origin; LDH, lactate dehydrogenase; ULN, upper limit of normal; NA, not available.
CSF vs parenchymal involvement not obtained.
Discrepancy between rates of GCB and CD10 positivity are the result of more missing data with respect to cell of origin.